CoChat
Sign Up
Cited by 3,011Hepatitis C virus researchLiver Disease Diagnosis and TreatmentLiver physiology and pathology

The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.

Natural history of liver fibrosis progression in patients with chronic hepatitis C

Poynard, Thierry, Bedossa, Pierre, Opolon, Pierre·1997·The Lancet
DOI 10.1016/s0140-6736(96)07642-8
Open this paper in CoChat — free account

Abstract

Background Our aim was to assess the natural history of liver fibrosis progression in hepatitis C and the factors associated with this progression. Methods We recruited 2235 patients from the Observatoire de l'Hépatite C (OBSVIRC) population, the Cohorte Hépatite C Pitié-Salpétrière (DOSVIRC) population, and the original METAVIR population. All the patients had a biopsy sample compatible with chronic hepatitis C as assessed by the METAVIR scoring system (grades the stage of fibrosis on a five-point scale, F0 = no fibrosis, F4 = cirrhosis, and histological activity on a four-point scale, A0 = no activity, A3 = severe activity). No patient had received interferon treatment before the liver biopsy sample was obtained. We assessed the effect of nine factors on fibrosis progression: age at biopsy; estimated duration of infection; sex; age at infection; alcohol consumption; hepatitis C virus C (HCV) genotype; HCV viraemia; cause of infection; and histological activity grade. We defined fibrosis progression per year as the ratio between fibrosis stage in METAVIR units and the duration of infection (1 unit = one stage, 4 units = cirrhosis). Findings The median rate of fibrosis progression per year was 0.133 fibrosis unit (95% CI 0.125-0.143), which was similar to the estimates from previous studies (0.146 to 0.154). Three independent factors were associated with an increased rate of fibrosis progression: age at infection older than 40 years, daily alcohol consumption of 50 g or more, and male sex. There was no association between fibrosis progression and HCV genotype. The median estimated duration of infection for progression to cirrhosis was 30 years (28-32), ranging from 13 years in men infected after the age of 40 to 42 years in women who did not drink alcohol and were infected before the age of 40. Without treatment, 377 (33%) patients had an expected median time to cirrhosis of less than 20 years, and 356 (31%) will never progress to cirrhosis or will not progress for at least 50 years. Interpretation The host factors of ageing, alcohol consumption, and male sex have a stronger association with fibrosis progression than virological factors in HCV infection.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(96)07642-8

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 24 references

Research works printed but not linked: 1

  1. 1995, Bilan initial. Association Francoise pour ľEtude du Foie, Lyon 1994, Gastroenterol Clin Biol, 19, 81

Cited by

Sorted by citations

Items 301–400 of 1,001

Related

See all

Metadata

Authors
Poynard, T., Bedossa, P., & Opolon, P.
Affiliations
Centre National de la Recherche Scientifique (FR)
Corresponding author
Poynard, Thierry
ORCID
Poynard, Thierry
Venue
The Lancet
Publisher
Elsevier BV
Published
1997-03
Volume
349
Issue
9055
Pages
825-832
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
DOI
10.1016/s0140-6736(96)07642-8
OpenAlex
W2132290252
Cited by
3,011
References
24
Citations by year
2026: 16 · 2025: 35 · 2024: 33 · 2023: 38 · 2022: 43 · 2021: 45 · 2020: 71 · 2019: 74 · 2018: 72 · 2017: 90 · 2016: 117 · 2015: 141 · 2014: 120 · 2013: 138 · 2012: 114
FWCI
60.07
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Association pour la Recherche sur le Cancer
  • Assistance Publique - Hôpitaux de Paris
  • Assistance publique-Hôpitaux de Paris
Topics
  • Health Sciences › Medicine › Hepatology › Hepatitis C virus research
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords
chronic hepatitis C, liver fibrosis progression, natural history (disease), METAVIR scoring, liver cirrhosis, age at infection, alcohol consumption, sex differences, HCV genotypes, HCV viraemia, host factors, infection duration, histological activity, liver biopsy
MeSH terms
Adult, Age Factors, Alcohol Drinking, Biopsy, Cross-Sectional Studies, Female, Hepatitis, Chronic, Hepatitis C, Humans, Liver, Liver Cirrhosis, Male, Middle Aged, Risk Factors, Sex Factors, Time Factors, Prevalence, Disease Progression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review